Since 1988, when the U.S. Food and Drug Administration approved proton therapy to treat cancer patients, the medical community has been conducting clinical trials to investigate the use of protons in treating different types of cancer. Over the years, many patients have volunteered to take part in these clinical trials to help find improvements in fighting cancer with proton therapy.
As a dedicated provider of proton therapy, ProCure is always looking for ways to improve the lives of our patients with cancer. Our team has made a commitment to participate in clinical trials to further our knowledge of the benefits of proton therapy in treating many tumor types. In addition, ProCure continues to pioneer advancements in the use of proton therapy for treating cancer and other diseases.
What Are Clinical Trials?
Clinical trials are research studies that involve people. They are the final step in a long process that begins with research in a lab. Each study answers a specific set of scientific questions and explores better ways to prevent, screen for, diagnose, or treat a disease. Most cancer treatments used today are the results of past clinical trials.
What Are Protocols?
For every clinical trial, a protocol, or action plan, is prepared prior to conducting the trial. The protocol describes in detail what will be done in the study, how it will be conducted, and why each part of the study is necessary. Each study has its own rules about who can participate. For instance, some studies need patients with a certain condition, some need healthy people, and some need just men or just women.
Clinical Trials at this ProCure Center
- PCG REG001-09/NCT01255748: Patients Treated with Proton Therapy
A registry trial to collect and analyze information from patients treated with proton therapy.
- PCG GU002-10/NCT01230866: Low-risk Prostate Cancer (standard fractionation vs hypo-fractionation)
A phase III, prospective, randomized trial comparing the effects (good and bad) on patients with low-risk prostate cancer by comparing the standard number of radiation treatments (44 treatments over 8.5-9 weeks) with a short course of radiation (5 treatments over 1-2 weeks) using higher radiation dose per treatment to see if the effects of the treatments are similar or better.
- PCG GU003-10/NCT01492972: Intermediate-risk Prostate Cancer
A phase III, prospective, randomized trial comparing the effects (good and bad) of hypofractionated proton therapy (28 treatments) with or without androgen suppression therapy on patients with intermediate-risk prostate cancer.
- UPCC 23309/NCT01126476: Recurrent Tumors
A study to determine the feasibility of using proton radiotherapy in recurrent malignancies. Patients with histologically confirmed, non-CNS solid malignancies who have been previously radiated and have a tumor recurrence in or near prior radiation fields can participate in the trial.
- PCG BRE007-12/NCT01766297: Early Stage Breast Cancer
A phase II, prospective, randomized trial comparing the effects (good and bad) on women with early stage breast cancer using proton radiation therapy.
- PCG BRE008-12/NCT01758445: Stage III Breast Cancer
A study to look at the rates of acute and long-term adverse events of postoperative proton radiotherapy for complex loco-regional irradiation in women with loco-regionally advanced breast cancer. This study specifically includes longitudinal follow up to assess the incidence of cardiac mortality and second malignant neoplasms at 10 and 15 years following proton therapy.
How Can I Find Clinical Trials?
You can search for more clinical trials by visiting http://www.clinicaltrials.gov
How Can I Participate in a Clinical Trial?
If you are interested in participating in a trial listed above, please contact a member of our research team and we will help you with next steps.
OklahomaTisha Adams, Clinical Research Coordinator
Email address: firstname.lastname@example.org